Develops drugs for rare diseases and chronic conditions.
Jun 2026Revenue $978M/yrExpenses $828M/yr
No trend
Figures by year
Is ANI Pharmaceuticals profitable?
Yes. In the 12 months to Jun 2026, revenue was $978M and expenses $828M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $883M | $772M | $111M |
| Dec 2024 | $614M | $614M | $584K |
| Dec 2023 | $487M | $440M | $47.0M |
| Dec 2022 | $316M | $352M | −$35.3M |
| Dec 2021 | $216M | $256M | −$39.8M |
| Dec 2020 | $208M | $224M | −$16.0M |
| Dec 2019 | $207M | $190M | $16.4M |
| Dec 2018 | $202M | $166M | $35.4M |
| Dec 2017 | $177M | $149M | $28.3M |
| Dec 2016 | $129M | $109M | $20.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.